Risk factors and treatment of stroke at the time of recurrence

Acta Neurologica Belgica

Volumn 110, Issue 4, 2010, Pages 299-302

  Laloux, P ^a   Lemonnier, F ^a   Jamart, J ^b  

^a UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Atrial fibrillation; Hypercholesterolemia; Hypertension; Recurrence; Risk factors; Secondary prevention; Stroke; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CIGARETTE SMOKING; CLINICAL EVALUATION; CLINICAL PRACTICE; DIABETES MELLITUS; DISEASE CLASSIFICATION; FEMALE; HEART ATRIUM FIBRILLATION; HOSPITAL ADMISSION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC EXAMINATION; PATIENT SATISFACTION; PHYSICAL ACTIVITY; PROSPECTIVE STUDY; RECURRENT DISEASE; RISK FACTOR; SECONDARY PREVENTION; SMOKING CESSATION; TRANSIENT ISCHEMIC ATTACK;

EID: 79551642193     PISSN: 03009009     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Petty GW, Brown RD, Whisnant JP, Sicks JD, O'Fallon WM. et al. Survival and recurrence after first cerebral infarction. A population-based study in rochester, minnesota, 1975 through 1989. Neurology. 1998;50:208-216.
2. Steg PG, Bhatt DL, Wilson PW, D'Agostino R Sr, Ohman EM. et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA: The Journal of the American Medical Association. 2007;297:1197-1206.
3. Rother J, Alberts MJ, Touze E, Mas JL, Hill MD. et al. Risk factor profile and management of cerebrovascular patients in the reach registry. Cerebrovasc Dis. 2008;25:366-374.
4. National Institute of Neurological Disorders and Stroke. Special report from the national institute of neurological disorders and stroke: Classification of cerebrovascular diseases iii. Stroke. 1990;21:637-676.
5. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, et al. Classification of subtype of acute ischemic stroke: Definitions for use in a multicenter clinical trial. Stroke. 1993;24:35-41.
6. Leoo T, Lindgren A, Petersson J, von Arbin M. Risk factors and treatment at recurrent stroke onset: Results from the recurrent stroke quality and epidemiology (RESQUE) study. Cerebrovasc Dis. 2008;25: 254-260. (Pubitemid 351450429)
7. Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of ischemic stroke subtypes according to TOAST criteria: Incidence, recurrence, and long-term survival in ischemic stroke subtypes: A population-based study. Stroke. 2001;32:2735-2740.
8. Progress Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
9. Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K. et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: Principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36: 1218-1224.
10. Amarenco P, Goldstein LB, Szarek M, Sillesen H, Rudolph AE. et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: The stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial. Stroke. 2007;38:3198-3204.
11. Collins R, Armitage J, Parish S, Sleight P, Peto R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363:757-767.
12. Antiplatelet Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
13. Hacke W, Kaste M, Olsen TS, Orgogozo JM, Bogousslavsky J. Recommendations of the European stroke initiative for the management and treatment of stroke. Nervenarzt. 2001;72:807-819. (Pubitemid 32973156)
14. Deplanque D, Leys D, Parnetti L, Schmidt R, Ferro J. et al. Secondary prevention of stroke in patients with atrial fibrillation: Factors influencing the prescription of oral anticoagulation at discharge. CerebrovascDis. 2006;21:372-379.
15. Weimar C, Benemann J, Katsarava Z, Weber R, Diener HC. Adherence and quality of oral anticoagulation in cerebrovascular disease patients with atrial fibrillation. Eur Neurol. 2008;60:142-148.
16. Algra A, Van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischemia of arterial origin. J Neurol Neurosurg Psychiatry. 1999;66:255.
17. Adams RJ, Albers G, Alberts MJ, Benavente O, Furie K. et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2008;39: 1647-1652.
18. Carolei A, Chamorro A, Laloux P, Leys D, Rother J. et al. Identification and management of polyvascular disease in patients with noncardioembolic ischaemic stroke. Int J Stroke. 2008;3:237-248.